Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

NCT00626795 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT00626795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00626795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
Lead sponsor
LEO Pharma
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
June 30, 2009
Enrollment
773 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

impetigo, secondarily infected traumatic lesions